RegulatoryCompany release

FDA clears Metagenomi IND for one-time hemophilia A gene-editing therapy MGX-001

🇺🇸 Metagenomi Therapeutics, Inc. (MGX) · Tue 10 Nov 2026

Metagenomi plans to open the Phase 1/2 INTEGR8 trial in the first half of 2027, with first clinical data expected in the second half of that year.

Metagenomi Therapeutics said on 10 November 2026 that the US Food and Drug Administration has cleared its investigational new drug (IND) application for MGX-001, an in vivo genome editing treatment for hemophilia A that is intended as a one-time therapy.

The clearance allows the company to begin a Phase 1/2 study named INTEGR8. Metagenomi expects to start the trial in the first half of 2027 and to report initial clinical data in the second half of 2027.

The company announced the news alongside its third-quarter 2026 financial results. It reported cash of $101.7 million and said this should fund operations into 2028.

For context, an IND clearance means the FDA has reviewed the submitted preclinical and manufacturing information and has not placed the study on clinical hold, so human testing can begin. It is not an assessment of efficacy or an approval to market.

What it means for your team

  • MGX-001 enters clinical development in 2027, adding another in vivo gene-editing candidate to the hemophilia A pipeline, which already includes established treatments.
  • Safety and long-term follow-up data from INTEGR8 will matter to pharmacovigilance teams, as a one-time editing therapy raises questions about durability and delayed adverse events.
  • Market-access teams should note that first clinical data are not expected until the second half of 2027, so any pricing or reimbursement implications remain distant.

Company's press release (SEC filing): Metagenomi Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Metagenomi Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →